Q2 2026 Vanda Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Fanapt continues to show strong growth, with TRx up 31% and NBRx up 32% year-over-year in Q2 2026, and has become one of the fastest-growing antipsychotics in the market.
- BYSANTI received FDA approval for bipolar I disorder and schizophrenia, with data exclusivity through 2031 and patent protection until 2044, and is on track for launch in H2 2026.
- NEREUS has launched commercially, with early direct-to-consumer sales and a positive Phase III study for GLP-1-induced vomiting, supporting potential supplemental NDA filing.
- Quimilza (imsidolimab) is under FDA review with a PDUFA date of December 12, 2026, and has received orphan drug designations in the US, Japan, and Europe, strengthening its market potential.
- The company expects operating expenses to decrease by the end of 2026 and more substantially in 2027, as Phase III programs and launch preparations conclude, improving future cash flow.
- HETLIOZ revenue continues to decline significantly due to generic competition, with a 42% decrease in H1 2026 and a 66% drop in Q2 2026, exacerbated by shipment timing issues.
- The company reported a net loss of $62.5 million in Q2 2026, a significant increase from the $27.2 million loss in Q2 2025, driven by higher operating expenses.
- Cash reserves decreased to $170 million as of June 30, 2026, down from $263.8 million at the end of 2025, with a cash burn expected to be higher in 2026 than in 2025.
- NEREUS revenue is constrained due to uncertainties in patient demand and product returns, with only $1 million recognized in Q2 2026 despite $15.2 million in wholesaler stocking.
- The company faces ongoing legal and regulatory uncertainties, including the FDA hearing for HETLIOZ in jet lag disorder, which is not expected to conclude until early 2027.
Good afternoon and welcome to the second quarter 2026 Vanda Pharmaceuticals Incorporated earnings conference call. I am France, and I'll be the operator assisting you today. (Operator Instructions) Thank you.
I would now like to turn the call over to Vanda's Chief Financial Officer, Kevin Moran. Please go ahead.
Thank you, France. Good afternoon and thank you for joining us to discuss Vanda Pharmaceuticals' second-quarter 2026 performance. Our second-quarter 2026 results were released this afternoon and are available on the SEC's EDGAR system and on our website, www.vandapharma.com. In addition, we are providing live and archived versions of this conference call on our website. Joining me on today's call is Dr. Mihael Polymeropoulos, our President, Chief Executive Officer, and Chairman of the Board, and Daniel M. McGuire, our General Counsel. Following my introductory remarks, Mihael
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
